10-Q quarterly report · filed Nov 3, 2026

ARVINAS, INC. (ARVN) Q3 2026 10-Q Quarterly Report

Short answer

ARVINAS, INC. (ARVN) filed its Q3 2026 10-Q quarterly report on Nov 3, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $500,000 (down 98.8% year over year) with net income of −$54M.

Q3 2026 key financials · XBRL

Revenue
$500,000
−98.8% YoY · −99.8% QoQ
Net income
−$54M
−53.6% YoY · −131.8% QoQ
Operating margin
-11820.0%
EPS (diluted)
−$0.82
−70.8% YoY · −131.5% QoQ

Source: XBRL data from the ARVINAS, INC. (ARVN) Q3 2026 10-Q on SEC EDGAR. USD.

ARVINAS, INC. Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Q3 revenue $0.5M, down $41.4M YoY from $41.9M, reflecting nonrecurring collaboration and milestone revenue
  • Q3 net loss $53.9M vs $35.1M YoY, with R&D expense $46.9M vs $64.7M
  • Best R&D growth: ARV-393 expense $5.8M vs $2.6M; worst: vepdegestrant expense $0 vs $14.2M
  • Cash, equivalents, restricted cash and marketable securities $558.9M vs $685.4M at December 31, 2025; operating cash use $127.9M
  • Funding runway into second half of 2028; ARV-102 PSP trial on clinical hold pending FDA review

Risk Factors

  • New risk triggered by AI deployment: AI and machine learning use in PROTAC discovery introduces data, cybersecurity, intellectual-property and operational exposure
  • Most materially updated risk: Rigel now controls VEPPANU pricing, reimbursement, sublicensing and ex-U.S. regulatory decisions
  • Regulatory risk: EU AI Act became fully effective in August 2026, increasing high-risk AI compliance obligations
  • Operational risk: VEPPANU commercialization depends entirely on Rigel’s funding and execution
  • Financial risk: No committed external funding source before substantial product-sale revenue generation

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other ARVINAS, INC. quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.